92 related articles for article (PubMed ID: 9600633)
1. Intraventricular insulin reduces the antinociceptive effect of [D-Ala2, NMePhe4, Gly-ol5]enkephalin in mice.
Kamei J; Ohsawa M; Sodeyama M; Kimura M; Tanaka S
Eur J Pharmacol; 1998 Mar; 345(2):171-4. PubMed ID: 9600633
[TBL] [Abstract][Full Text] [Related]
2. Possible mechanisms for insulin-induced attenuation of the antinociceptive effect of [D-Ala2, N-MePhe4, Gly-ol5]enkephalin.
Ohsawa M; Tanaka S; Kamei J
Eur J Pharmacol; 1999 Jun; 373(2-3):181-6. PubMed ID: 10414437
[TBL] [Abstract][Full Text] [Related]
3. Possible involvement of protein kinase C in the attenuation of [D-Ala2, NMePhe4, Gly-ol5]enkephalin-induced antinociception in diabetic mice.
Ohsawa M; Kamei J
Eur J Pharmacol; 1997 Nov; 339(1):27-31. PubMed ID: 9450613
[TBL] [Abstract][Full Text] [Related]
4. A Tyr-W-MIF-1 analog containing D-Pro2 discriminates among antinociception in mice mediated by different classes of mu-opioid receptors.
Nakayama D; Watanabe C; Watanabe H; Mizoguchi H; Sakurada T; Sakurada S
Eur J Pharmacol; 2007 Jun; 563(1-3):109-16. PubMed ID: 17343845
[TBL] [Abstract][Full Text] [Related]
5. Pretreatment with protein kinase C activator phorbol 12,13-dibutyrate attenuates the antinociception induced by mu- but not epsilon-opioid receptor agonist in the mouse.
Narita M; Ohsawa M; Mizoguchi H; Kamei J; Tseng LF
Neuroscience; 1997 Jan; 76(1):291-8. PubMed ID: 8971779
[TBL] [Abstract][Full Text] [Related]
6. Role of intracellular calcium in modification of mu and delta opioid receptor-mediated antinociception by diabetes in mice.
Ohsawa M; Nagase H; Kamei J
J Pharmacol Exp Ther; 1998 Aug; 286(2):780-7. PubMed ID: 9694934
[TBL] [Abstract][Full Text] [Related]
7. Lack of antinociceptive cross-tolerance between [D-Pen2, D-Pen5]enkephalin and [D-Ala2]deltorphin II in mice: evidence for delta receptor subtypes.
Mattia A; Vanderah T; Mosberg HI; Porreca F
J Pharmacol Exp Ther; 1991 Aug; 258(2):583-7. PubMed ID: 1650835
[TBL] [Abstract][Full Text] [Related]
8. Effect of MK-801 on the antinociceptive effect of [D-Ala(2),N-MePhe(4), Gly-ol(5)]enkephalin in diabetic mice.
Zushida K; Kamei J
Eur J Pharmacol; 2002 Jul; 448(1):39-44. PubMed ID: 12126969
[TBL] [Abstract][Full Text] [Related]
9. Buprenorphine blocks epsilon- and micro-opioid receptor-mediated antinociception in the mouse.
Mizoguchi H; Spaulding A; Leitermann R; Wu HE; Nagase H; Tseng LF
J Pharmacol Exp Ther; 2003 Jul; 306(1):394-400. PubMed ID: 12721333
[TBL] [Abstract][Full Text] [Related]
10. Differential contribution of descending serotonergic and noradrenergic systems to central Tyr-D-Ala2-Gly-NMePhe4-Gly-ol5 (DAMGO) and morphine-induced antinociception in mice.
Arts KS; Holmes BB; Fujimoto JM
J Pharmacol Exp Ther; 1991 Mar; 256(3):890-6. PubMed ID: 2005587
[TBL] [Abstract][Full Text] [Related]
11. Delta opioid receptor enhancement of mu opioid receptor-induced antinociception in spinal cord.
He L; Lee NM
J Pharmacol Exp Ther; 1998 Jun; 285(3):1181-6. PubMed ID: 9618421
[TBL] [Abstract][Full Text] [Related]
12. Reduction in [D-Ala2, NMePhe4, Gly-ol5]enkephalin-induced peripheral antinociception in diabetic rats: the role of the L-arginine/nitric oxide/cyclic guanosine monophosphate pathway.
Tasatargil A; Sadan G
Anesth Analg; 2004 Jan; 98(1):185-192. PubMed ID: 14693616
[TBL] [Abstract][Full Text] [Related]
13. Heroin acts on different opioid receptors than morphine in Swiss Webster and ICR mice to produce antinociception.
Rady JJ; Roerig SC; Fujimoto JM
J Pharmacol Exp Ther; 1991 Feb; 256(2):448-57. PubMed ID: 1847196
[TBL] [Abstract][Full Text] [Related]
14. An examination of the relationship between mu-opioid antinociceptive efficacy and G-protein coupling using pertussis and cholera toxins.
Goode TL; Raffa RB
Life Sci; 1997; 60(7):PL107-13. PubMed ID: 9042382
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of protein kinase C, but not of protein kinase A, blocks the development of acute antinociceptive tolerance to an intrathecally administered mu-opioid receptor agonist in the mouse.
Narita M; Narita M; Mizoguchi H; Tseng LF
Eur J Pharmacol; 1995 Jul; 280(2):R1-3. PubMed ID: 7589170
[TBL] [Abstract][Full Text] [Related]
16. Selective antagonism by naloxonazine of antinociception by Tyr-D-Arg-Phe-beta-Ala, a novel dermorphin analogue with high affinity at mu-opioid receptors.
Sakurada S; Takeda S; Sato T; Hayashi T; Yuki M; Kutsuwa M; Tan-No K; Sakurada C; Kisara K; Sakurada T
Eur J Pharmacol; 2000 Apr; 395(2):107-12. PubMed ID: 10794815
[TBL] [Abstract][Full Text] [Related]
17. Evidence for differential modulation of mu-opioid receptor-mediated antinociceptive and antitussive activities by spleen-derived factor(s) from diabetic mice.
Kamei J; Iwamoto Y; Misawa M; Nagase H; Kasuya Y
Neuropharmacology; 1994 Dec; 33(12):1553-8. PubMed ID: 7760978
[TBL] [Abstract][Full Text] [Related]
18. The effect of pretreatment with a delta 2-opioid receptor antisense oligodeoxynucleotide on the recovery from acute antinociceptive tolerance to delta 2-opioid receptor agonist in the mouse spinal cord.
Narita M; Mizoguchi H; Kampine JP; Tseng LF
Br J Pharmacol; 1997 Feb; 120(4):587-92. PubMed ID: 9051295
[TBL] [Abstract][Full Text] [Related]
19. Streptozotocin-induced diabetes selectively alters the potency of analgesia produced by mu-opioid agonists, but not by delta- and kappa-opioid agonists.
Kamei J; Ohhashi Y; Aoki T; Kawasima N; Kasuya Y
Brain Res; 1992 Feb; 571(2):199-203. PubMed ID: 1319265
[TBL] [Abstract][Full Text] [Related]
20. Pretreatment with pertussis toxin differentially modulates morphine- and beta-endorphin-induced antinociception in the mouse.
Tseng LF; Collins KA
J Pharmacol Exp Ther; 1996 Oct; 279(1):39-46. PubMed ID: 8858973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
